A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Public ClinicalTrials.gov record NCT04802759. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)
Study identification
- NCT ID
- NCT04802759
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 316 participants
Conditions and interventions
Interventions
- Abemaciclib Drug
- Atezolizumab Drug
- Everolimus Drug
- Giredestrant Drug
- Inavolisib Drug
- Ipatasertib Drug
- PH FDC SC Drug
- Palbociclib Drug
- Ribociclib Drug
- Samuraciclib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 21, 2021
- Primary completion
- May 29, 2029
- Completion
- May 29, 2029
- Last update posted
- Apr 12, 2026
2021 – 2029
United States locations
- U.S. sites
- 11
- U.S. states
- 6
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | Recruiting |
| University of California, San Francisco (UCSF) | San Francisco | California | 94143 | Recruiting |
| Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Santa Monica | California | 90404 | Recruiting |
| Stanford Cancer Institute (SCI) | Stanford | California | 94305 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
| Regional Cancer Care Associates LLC (RCCA) - Freehold Location | Freehold | New Jersey | 07728 | Withdrawn |
| Regional Cancer Care Associates LLC ? Howell Division | Howell Township | New Jersey | 07731 | Withdrawn |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | Recruiting |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | Recruiting |
| University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania | 15219 | Withdrawn |
| West Cancer Center | Germantown | Tennessee | 38138 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04802759, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2026 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04802759 live on ClinicalTrials.gov.